Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

October 08, 2009 11:16 ET

Notice of Thallion Pharmaceuticals 2009 Third Quarter Conference Call

Third quarter financial results to be released on October 14, 2009

MONTREAL, QUEBEC--(Marketwire - Oct. 8, 2009) - Thallion Pharmaceuticals Inc. (TSX:TLN) will release its 2009 third quarter financial results on Wednesday, October 14, 2009 after 4:00 PM Eastern Time. The Company will subsequently hold a conference call on Wednesday, October 14, 2009 at 4:30 PM Eastern Time hosted by Mr. Lloyd M. Segal, Chief Executive Officer and Mr. Michael Singer, Chief Financial Officer. A question and answer session will follow the corporate update.



CONFERENCE CALL DETAILS

DATE: October 14, 2009

TIME: 4:30 PM Eastern Time

DIAL IN NUMBER: 416-644-3423 or 1-800-589-8577

TAPED REPLAY: 416-640-1917 or 1- 877-289-8525

REFERENCE NUMBER: 4170511#


A live audio webcast of the conference call will be available by visiting the Company's website at www.thallion.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease. The Company's clinical programs include TLN-4601 and Shigamabs®. TLN-4601 is a novel anti-cancer therapy targeting the RAS-MAPK pathway which is actively enrolling patients at multiple sites in Canada and the United States in a Phase II trial for brain cancer. Shigamabs® is a dual antibody product for the treatment of Shigatoxin producing E. coli bacterial infections which is ready to begin a Phase II/III clinical program upon the completion of a development partnership. Additional information about Thallion can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of regulatory approvals and consents, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Contact Information